Sanofi–Translate Bio COVID-19 vaccine

Sanofi–Translate Bio COVID-19 vaccine
Vaccine description
Target	SARS-CoV-2
Vaccine type	mRNA
Clinical data
Other names	MRT5500, VAW00001
Routes of; administration	Intramuscular
Legal status
Legal status	Terminated[1];

The Sanofi–Translate Bio COVID-19 vaccine, also known as MRT5500 or VAW00001, was a COVID-19 vaccine candidate developed by Sanofi Pasteur and Translate Bio.[2][3] The development was stopped in September 2021.[4]

History

In June 2020, Sanofi, after lagging behind its competitors, "accelerated" the development of the vaccine via the smaller biotech firm Translate Bio, with a US$425 million partnership.[5]

Development of the vaccine halted in September 2021, with Sanofi citing the difficulty of running placebo-controlled studies with other mRNA vaccines (such as Pfizer's and Moderna's) already on the market. Despite this, the company reported "promising results" in its initial trials.[4]Sanofi has continued testing its recombinant protein vaccine, developed collaboratively with GlaxoSmithKline, to serve as a booster dose for other COVID-19 vaccines.[4]

References

Abboud L (28 September 2021). "Sanofi stops development of Covid vaccine based on mRNA technology". Financial Times.
"Sanofi and Translate Bio initiate Phase 1/2 clinical trial of mRNA COVID-19 vaccine candidate". Sanofi. 12 March 2021. Archived from the original on 9 October 2021. Retrieved 20 March 2021.
"Study of mRNA Vaccine Formulation Against COVID-19 in Healthy Adults 18 Years of Age and Older (VAW00001)". United States National Library of Medicine. Retrieved 20 March 2021.
"Sanofi drops plans for messenger RNA vaccine against virus". Associated Press. 28 September 2021. Archived from the original on 14 October 2021. Retrieved 7 October 2021.
Branswell H, Feuerstein A (23 June 2020). "Sanofi, a straggler in the Covid-19 vaccine race, accelerates its plans". STAT. Archived from the original on 20 October 2021. Retrieved 7 August 2020.

External links

This article is issued from Wikipedia. The text is licensed under Creative Commons - Attribution - Sharealike. Additional terms may apply for the media files.

[1] Abboud L (28 September 2021). "Sanofi stops development of Covid vaccine based on mRNA technology". Financial Times.

[2] "Sanofi and Translate Bio initiate Phase 1/2 clinical trial of mRNA COVID-19 vaccine candidate". Sanofi. 12 March 2021. Archived from the original on 9 October 2021. Retrieved 20 March 2021.

[3] "Study of mRNA Vaccine Formulation Against COVID-19 in Healthy Adults 18 Years of Age and Older (VAW00001)". United States National Library of Medicine. Retrieved 20 March 2021.

[apc-4] "Sanofi drops plans for messenger RNA vaccine against virus". Associated Press. 28 September 2021. Archived from the original on 14 October 2021. Retrieved 7 October 2021.

[5] Branswell H, Feuerstein A (23 June 2020). "Sanofi, a straggler in the Covid-19 vaccine race, accelerates its plans". STAT. Archived from the original on 20 October 2021. Retrieved 7 August 2020.